qMonthly
Welcome to qMonthly, a blog written by Dr. Mike Fralick edited by Katarina Zorcic. Mike is a general internist at Sinai Health in Toronto and The Sault Area Hospital in Sault Ste Marie and a Deputy Editor with NEJM Evidence.
Dr. Mike Fralick
Katarina Zorcic
The headliner: Beta-blockers offer no benefit after MI when LVEF is preserved
The headliner: Beta-blockers offer no benefit after MI when LVEF is preserved
For decades, beta-blockers after myocardial infarction have been treated as default therapy, but this practice has been supported by trials that date back to the 1980s. Enter this large individual-patient meta-analysis, pooling 17,801 patients across five recent randomized trials of patients with recent MI and LVEF ≥50% and no other indication for beta-blockers. The primary composite outcome (death, MI, or heart failure) occurred in 8.1% of patients on beta-blockers and 8.3% of those not treated (HR 0.97; 95% CI 0.87–1.07), showing no meaningful difference. None of the individual components—death, recurrent MI, or heart failure—were improved with therapy. In short, for post-MI patients with preserved LVEF, routine beta-blockers don’t improve outcomes and may represent yet another legacy practice ready for retirement.
The hidden gem: Spironolactone for patients on dialysis doesn’t improve CV endpoints
Patients with end-stage renal disease requiring dialysis are at high risk of subsequent cardiovascular events. The ACHIEVE trial sought to determine if spironolactone can reduce this risk. It was an international, placebo-controlled, double-blind trial, and the primary endpoint was a composite of CV mortality or hospitalization for heart failure. Following a planned interim analysis, the external safety and efficacy monitoring committee recommended stopping the trial early due to futility. Overall, 2538 were randomly assigned to spironolactone (n=1260) or placebo (n=1278). The composite primary outcome occurred in 258 participants in the spironolactone group and in 276 participants in the placebo group (hazard ratio [HR] 0·92 [95% CI 0·78–1·09]; p=0·35).
The take home points:
[1] In patients with preserved LVEF (≥50%) and no other indication, beta-blockers offered no reduction in death, MI, or HF.
[2] Spironolactone did not reduce CV death or HF hospitalization in patients on dialysis, leading to early termination for futility.
Previous Posts
The headliner: Arterial lines are likely unnecessary for critically ill patients with shock
The headliner: Arterial lines are likely unnecessary for critically ill patients with shock Back when I was an intern in the ICU, arterial line insertion was near universal for patients. But this practice is primarily based on historical precedent rather than...
The headliner: Anticoagulants + Aspirin = death.
This is a special edition summarizing three studies from the recent European Society of Cardiology (ESC) Conference hosted from August 29 to September 1, 2025. Preamble: If my math is correct, there were at least five practice-changing trials published at ESC. All...
The headliner: As needed albuterol+budesnide in mild asthma for the win!
The headliner: As needed albuterol+budesnide in mild asthma for the win! Prior trials have shown that as needed albuterol+budesonide in a combination inhaler, compared to albuterol-alone, reduces asthma exacerbations among adults with moderate to severe asthma. But...
The headliner: A powerful duo for diabetic nephropathy: finerenone + empagliflozin.
The headliner: A powerful duo for diabetic nephropathy: finerenone + empagliflozin. What happens if we start both drugs at once instead of choosing one? The CONFIDENCE trial tested whether initial combination therapy with both drugs is more effective than either drug...
The headliner: Once-monthly GLP1-GIP medication leads to 15% weight loss.
This is a special edition summarizing three studies from the recent American Diabetes Association Conference hosted in June 2025. The headliner: Once-monthly GLP1-GIP medication leads to 15% weight loss. Yes, you read that correctly; MariTide (Maridebart...
The headliner: Tirzepatide (Mounjaro) vs semaglutide (Ozempic). Who won?
The headliner: Tirzepatide (Mounjaro) vs semaglutide (Ozempic). Who won? Tirzepatide! A recently completed open-label RCT of over 700 adults with obesity showed that tirzepatide had superior weight loss compared to semaglutide. Specifically, patients randomized to...
The headliner: Should patients with heart failure restrict their fluid intake?
The headliner: Should patients with heart failure restrict their fluid intake? Probably not! While we counsel patients with heart failure to fluid restrict, this was based on lousy data. The results from the FRESH-UP trial showed no significant benefit of fluid...
The headliner: For patients with MI, liberal transfusion strategy improves outcomes.
The headliner: For patients with MI, liberal transfusion strategy improves outcomes. For most patients admitted into hospital, the typical threshold for transfusing red blood cells is 70 g/L (7 g/dL) based on the TRICC trial. But what about patients with myocardial...
Welcome to qMonthly
Welcome to qMonthly, a blog written by Dr. Mike Fralick edited by Katarina Zorcic. Mike is a general internist at Sinai Health in Toronto and The Sault Area Hospital in Sault Ste Marie and a Deputy Editor with NEJM Evidence. The headliner: Semaglutide reduces...
Join Our Email List!
Sign up here to receive qMonthly direct to your inbox